Welcome to Epistem

Epistem is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Founded on ground-breaking research in epithelial stem cell biology, Epistem has evolved into a dynamic and successful enterprise enabling advances in medicine through the provision of innovative services and pioneering products. For over ten years Epistem has been providing a personalised service to customers worldwide, from virtual start-ups to established biotechnology enterprises, global pharmaceutical and personal care companies.

Company Overview

Contract Research

Committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline.


Specialists in gene expression and DNA genotyping, providing GCLP accredited services to drug development and diagnostic programs.


A pioneering Point-of-Care molecular diagnostic platform providing low cost, high sensitivity, next generation genotyping and sequence analysis in under 60 minutes.

Novel Therapies

Utilising Epistem's scientific heritage and expertise to identify key regulators of epithelial stem cell and develop novel therapeutics with implications in both oncology and regenerative medicine.

  • Shares
  • News
  • Events
  • Twitter
  • Company Reports
  • Careers
  • Quality

Share Price

0p change
Last Updated:
Sat May 28 10:35
(15 min delay share price)

  • Upcoming Webinar to Examine Pre-Clinical Models of Intestinal Toxicity

    Tuesday May 24, 2016

    /EINPresswire.com/ -- TORONTO, ON--(Marketwired - May 24, 2016) - On Friday, June 10, 2016, at 10am EDT (3pm BST/UK), Xtalks will host a complimentary webinar featuring Cath Booth, Co-Founder and Managing Director of Contract Research Services at Epistem as the keynote speaker.

  • Epistem's diagnostic test scores well in hepatitis trial

    Tuesday May 03, 2016

    Epistem Holdings Plc’s (LON:EHP) rapid diagnostic system Genedrive has performed well in

  • Epistem funding from US Department of Defense

    Monday March 21, 2016

    StockMarketWire.com - The US Department of Defense has awarded Epistem $2.9m in funding for the next phase of its

  • Epistem makes progress on two diagnostic fronts

    Monday February 22, 2016

    (MENAFN - ProactiveInvestors - UK) To get a new technology accepted is never easy but Epistem (LON:EHP) is making progress on two fronts with its Genedrive diagnostic platform. A test for Hepatitis C (HCV) has just been cleared for clinical trials by the Institut Pasteur in Paris.

  • Update on CEO Appointment

    Friday February 19, 2016

    RNS Press Release For release: 19 February 2016 Update on CEO Appointment Epistem Holdings Plc (LSE: EHP), the

Prelim Results

Epistem releases Annual Report & Accounts to 30th June 2014.

View Annual Report.

Could you help Epistem provide specialist expertise and analyses on epithelial tissue and adult stem cells to the ever-demanding biotechnology and pharmaceutical industry?

If you are interested in a career with Epistem, contact us today with your details. Email your CV/resumé to jobs@epistem.co.uk

  • Epistem strives to become a world class biotechnology and personalised medicine company applying its expertise to all services provided. Epistem aims to improve services and treatments provided by the Healthcare industry.

  • Epistem is committed to ensuring accurate and timely provision of superior products and services and to continuously meet or exceed the stated or implied expectations of our customers.

  • Epistem is committed to the continuous improvement of its Quality Management System and compliance with the relevant regulatory requirements.

Copyright 2014 Epistem Holdings Plc